Investor Centre

Summit is publicly-listed in the UK (LSE) and US (NASDAQ)

Regulatory News

Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
VIEW NEWS
Summit Therapeutics to Present at the BIO CEO & Investor Conference
VIEW NEWS

Share Price

LSE: SUMM
At 20/02/2019 07:15
NASDAQ: SMMT
At 20/02/2019 07:15